Bionano Genomics Total Debt Growth & History (BNGO)
Bionano Genomics's total debt was $6.9M for fiscal 2025.
View full Bionano Genomics company overviewBionano Genomics annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.9M | −$20,000 | −0.29% |
| 2024 | 2024-12-31 | $6.9M | −$2.7M | −27.84% |
| 2023 | 2023-12-31 | $9.6M | −$2.1M | −17.64% |
| 2022 | 2022-12-31 | $11.7M | $972,000 | +9.09% |
| 2021 | 2021-12-31 | $10.7M | −$5.6M | −34.48% |
| 2020 | 2020-12-31 | $16.3M | −$3.8M | −18.72% |
| 2019 | 2019-12-31 | $20.1M | $11.1M | +122.44% |
| 2018 | 2018-12-31 | $9.0M | $2.3M | +34.17% |
| 2017 | 2017-12-31 | $6.7M | — | — |
Bionano Genomics quarterly total debt
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.7M | −$1.1M | −14.24% |
| Q1 2026 | 2026-03-31 | $6.9M | $1.5M | +27.67% |
| Q4 2025 | 2025-12-31 | $6.9M | −$20,000 | −0.29% |
| Q3 2025 | 2025-09-30 | $7.4M | −$130,000 | −1.73% |
| Q2 2025 | 2025-06-30 | $7.8M | −$394,000 | −4.80% |
| Q1 2025 | 2025-03-31 | $5.4M | −$3.4M | −38.84% |
| Q4 2024 | 2024-12-31 | $6.9M | −$2.7M | −27.84% |
| Q3 2024 | 2024-09-30 | $7.5M | −$2.6M | −26.05% |
| Q2 2024 | 2024-06-30 | $8.2M | −$2.5M | −23.00% |
| Q1 2024 | 2024-03-31 | $8.8M | −$2.4M | −21.33% |
| Q4 2023 | 2023-12-31 | $9.6M | −$2.1M | −17.64% |
| Q3 2023 | 2023-09-30 | $10.1M | −$250,000 | −2.41% |
| Q2 2023 | 2023-06-30 | $10.7M | −$93,000 | −0.86% |
| Q1 2023 | 2023-03-31 | $11.2M | $57,000 | +0.51% |
| Q4 2022 | 2022-12-31 | $11.7M | $972,000 | +9.09% |
| Q3 2022 | 2022-09-30 | $10.4M | $10.4M | — |
| Q2 2022 | 2022-06-30 | $10.8M | $10.8M | — |
| Q1 2022 | 2022-03-31 | $11.1M | −$3.8M | −25.23% |
| Q4 2021 | 2021-12-31 | $10.7M | −$5.6M | −34.48% |
| Q3 2021 | 2021-09-30 | $0 | −$16.0M | — |
| Q2 2021 | 2021-06-30 | $0 | −$15.7M | — |
| Q1 2021 | 2021-03-31 | $14.9M | −$2.1M | −12.39% |
| Q4 2020 | 2020-12-31 | $16.3M | −$3.8M | −18.72% |
| Q3 2020 | 2020-09-30 | $16.0M | −$2.8M | −14.72% |
| Q2 2020 | 2020-06-30 | $15.7M | −$2.9M | −15.62% |
| Q1 2020 | 2020-03-31 | $17.0M | −$1.4M | −7.66% |
| Q4 2019 | 2019-12-31 | $20.1M | $11.1M | +122.44% |
| Q3 2019 | 2019-09-30 | $18.8M | $9.8M | +108.44% |
| Q2 2019 | 2019-06-30 | $18.6M | — | — |
| Q1 2019 | 2019-03-31 | $18.4M | — | — |
| Q4 2018 | 2018-12-31 | $9.0M | $2.3M | +34.17% |
| Q3 2018 | 2018-09-30 | $9.0M | — | — |
| Q4 2017 | 2017-12-31 | $6.7M | — | — |
Bionano Genomics total debt trends
Over the last five fiscal years, Bionano Genomics's total debt decreased from $16.3M to $6.9M, a change of −$9.4M. The latest reported quarter, Q2 2026, shows $6.7M.
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bionano Genomics source filings ↗